Influenza Therapeutics Market Size
The global Influenza Therapeutics Market was valued at approximately US$ 9.36 billion in 2025 and is anticipated to reach around US$ 12.94 billion by 2033, growing at a CAGR of 4.1% during the forecast period 2026–2033.
Influenza is a flu-like illness caused by the influenza virus with symptoms such as chills, fever, etc. Most people contract the flu by breathing in tiny airborne droplets from the coughs or sneezes of already infected patients. The Centers for Disease Control and Prevention recommends people get flu shots annually to prevent serious risks that lead to death.
Outbreaks of influenza occur every year, and many people with flu-like symptoms use over-the-counter medication such as anti-viral drugs, anti-microbial drugs, etc. According to the World Health Organization (WHO), the annual global influenza attack rate ranges from 20% to 30% of the child population and around 10% of the adult population. The number of deaths due to influenza is approximately 290,000–650,000 annually.
Influenza Therapeutics Market Scope
| Metrics | Details |
| CAGR | High |
| Market Size | 2025-2033 |
| Market Estimation Forecast Period | 2026-2033 |
| Revenue Units | Value (US$ Mn) |
| Segments Covered | Disease Type, Therapeutics, Route of Administration, End User, and Region |
| Regions Covered | North America, Europe, Asia-Pacific, South America, and Middle East & Africa |
| Largest Region | North America |
| Fastest Growing Region | Asia Pacific |
| Report Insights Covered | Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and Acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, Porter’s Analysis, Pricing Analysis, Regulatory Analysis, Supply-Chain Analysis, and Other key Insights. |
For more details on this report Request for Sample
Influenza Therapeutics Market Dynamics
Increasing clinical trials
Clinical trials are ongoing for vaccines, testing their safety, immunogenicity, and efficacy profiles. These vaccines are developed to increase efficacy and safety and decrease the harmful effects. For instance, according to clinical.gov, Mahidol University and the Government Pharmaceutical Organization conduct phase 3 clinical trials to evaluate the immunogenicity and safety of Tri Fluvac, a seasonal trivalent inactivated split virion influenza vaccine. The start date is August 3, 2020. The estimated completion date is December 31, 2023.
The National Institute of Allergy and Infectious Diseases (NIAID) is conducting a phase 1 clinical trial to assess the safety and tolerability of a Mosaic Hexavalent Influenza Vaccine VRC-FLUMOS0116-00-VP (FluMos-v2) in Healthy Adults. The start date is August 9, 2023. The estimated completion date is December 16, 2024.
Nanjing Zenshine Pharmaceuticals conducts phase 2 and 3 trials to compare ZX-7101A in Chinese adult patients with uncomplicated influenza. The safety and efficacy of ZX-7101A is also assessed. The study start date is September 17, 2022. The estimated completion date is June 30, 2024.
Side effects of anti viral drugs
Influenza drug side effects are mild and treatable, such as nausea and vomiting. Few anti-viral drugs cause bronchospasm as well as diarrhea. Oral oseltamivir is recommended for pregnant women as other medications like Baloxavir have severe complications when taken by pregnant women or breastfeeding women, as there is no safety data available for this drug. Due to the underlying risks, Zanamivir is approved for early flu treatment in people seven years and older.
Influenza Therapeutics Market Segment Analysis
The global influenza therapeutics market is segmented based on disease type, therapeutics, route of administration end user and region.
The vaccines segment accounted for approximately 52.3% of the market share
Vaccines are the most effective treatment for influenza compared to drugs, as vaccines give long-term protection to the patient. mRNA vaccines work more precisely and quickly as they destroy the primary target and cure the disease. Vaccine manufacturers like Pfizer and Moderna are working on the launch of mRNA vaccines for influenza.
In September 2022, Pfizer Inc. initiated clinical trial phase 3 to evaluate the efficacy, tolerability, and immunogenicity of quadrivalent modified RNA (modRNA) influenza vaccine.
In February 2023, Moderna initiated a phase 3 clinical trial to assess the safety and efficacy of mRNA-1010, a seasonal influenza vaccine candidate.
Global Influenza Therapeutics Market Geographical Share
North America accounted for approximately 41.2% of the market share in 2022
North America is expected to hold the largest share in the market owing to the presence of giant vaccine manufacturers such as Pfizer, moderna, etc., and the increasing prevalence of the disease in the US, Canada, etc. Several people from flu belong to the North American region.
Influenza is a contagious disease which affects more that affects nearly 8% of the U.S. population annually. According to the World Health Organization (WHO), Seasonal influenza leads to an estimated 650,000 deaths worldwide yearly. More than 90% of influenza deaths occur in adults at least 65.
According to the Government of Canada's annual report on seasonal influenza, During the 2021–2022 influenza season, 16,126 laboratory-confirmed influenza detections were reported out of 751,900 total laboratory tests. Nearly 71% of seniors (65 and older) are affected by influenza yearly.
Influenza Therapeutics Market Companies
The major global players in the influenza therapeutics market include Merck KGaA, Santa Cruz Biotechnology, Inc., Biosynth, Teva Pharmaceuticals USA, Inc., Biorbyt Ltd., Thermo Fisher Scientific Inc., Steris, Healthcare PVT Ltd., Genentech, Inc., Lupin Pharmaceuticals, Inc., BioCryst Pharmaceuticals, Inc. among others.
Key Developments
- On April 2026, global market intelligence reports highlighted increasing demand for broad-spectrum antiviral drugs and next-generation influenza therapeutics, driven by rising seasonal flu cases and heightened pandemic preparedness strategies across North America and Asia-Pacific. Governments and health agencies are expanding antiviral stockpiles and accelerating procurement of neuraminidase inhibitors and polymerase inhibitors.
- On March 2026, several national healthcare systems, including those in Europe and Asia, expanded influenza preparedness programs by strengthening early warning surveillance systems and increasing investment in rapid diagnostic-linked antiviral distribution networks. This development is supporting faster treatment initiation and improving clinical outcomes in high-risk populations.
- On February 2026, pharmaceutical pipeline updates indicated a growing focus on universal influenza vaccine candidates and combination antiviral therapies, aimed at addressing drug resistance challenges. Clinical research activity intensified across mRNA-based and recombinant vaccine platforms, reflecting strong innovation momentum in the influenza therapeutics landscape.
- On January 2026, industry analysis reported steady expansion of the global influenza therapeutics market, driven by recurring seasonal outbreaks, increasing elderly population vulnerability, and rising adoption of outpatient antiviral treatment protocols. Growth is further supported by advancements in drug delivery systems and improved accessibility of prescription antivirals in emerging economies.
- On November 2025, market outlook reports noted supply chain stabilization for key antiviral ingredients following previous disruptions, along with improved manufacturing capacity for established influenza drugs. However, pricing pressure and generic competition continued to challenge revenue growth for branded antiviral therapies.
- On October 2025, research and development investments increased in novel neuraminidase inhibitors and cap-dependent endonuclease inhibitors, with several biotech firms advancing late-stage clinical trials. This reflects strong industry interest in overcoming resistance limitations associated with existing influenza treatments.
- On July 2025, global public health agencies emphasized strengthening influenza surveillance networks and increasing collaboration with pharmaceutical companies to ensure rapid response capability during peak flu seasons. This initiative is supporting higher uptake of preventive and therapeutic influenza solutions across hospitals and clinics.
Why Purchase the Report?
- To visualize the global influenza therapeutics market segmentation based on disease type, therapeutics, route of administration, end-user and region as well as understand key commercial assets and players.
- Identify commercial opportunities by analyzing trends and co-development.
- Excel data sheet with numerous data points of influenza therapeutics market-level with all segments.
- PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
- Product mapping available as Excel consisting of key products of all the major players.
The global influenza therapeutics market report would provide approximately 69 tables, 67 figures, and 195 Pages.
Target Audience
- Manufacturers/ Buyers
- Industry Investors/Investment Bankers
- Research Professionals
- Emerging Companies
